| |
| Exchange: |
|
| Security
Type: |
|
| Shares
Out: |
1,940,000,000 |
| Market
Cap: |
58.55(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$23.74 - $37 |
|
| Level
I Sector: |
|
| Level
II Sector: |
|
| Level
III Sector: |
|
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Daiichi Sankyo is mainly engaged in the research, development, manufacture, sale and marketing of pharmaceutical products. Co. offers prescription drugs, including "ENHERTU" for cancer treatments, anticoagulants "LIXIANA/SAVAYSA," antihypertensive agents "MINNEBRO," antipatelet agents "EFFIENT," "CANALLIA" for type 2 diabetes mellitus, "Injectafer" for iron deficiency anemia and "NEXIUM" for ulcers treatments, as well as influenza vaccines, measles/rubella vaccines and mumps vaccines. Co also manufactures over-the-counter drugs, cosmetics and medical equipment. Co. operates its business activities in Japan, the Americas, Europe, China and Asia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
0.60 (2.03%) 
